Neprilysin

Neprilysin

Neprilysin Molekülinformation

Molecule Name
Neprilysin
Molekülalias
MME,CALLA,CD10,DKFZp686O16152,MGC126681,MGC126707,NEP,SFE,Neprilysin
Drug Development Progress
Anzahl der klinischen Arzneimittel8
Anzahl der inverkehr gebrachten Arzneimittel3
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
EC:3.4.24.11,EC 3.4.24,Atriopeptidase,NEP,SFE,Membrane Metallo-Endopeptidase (Neutral Endopeptidase, Enkephalinase, CALLA, CD10),Membrane Metallo-Endopeptidase Variant 1,Membrane Metallo-Endopeptidase Variant 2,Neprilysin-390,Neprilysin-411,CD10 Antigen,EC 3.4.24.11,CMT2T,SCA43,EPN,MME,Enkephalinase,CALLA,Neutral endopeptidase,Common acute lymphocytic leukemia antigen,Neprilysin,CD10,Membrane Metalloendopeptidase,Neutral Endopeptidase 24.11,Skin fibroblast elastase
Molekülhintergrund
Cluster of differentiation 10 (CD10) is also known as membrane metallo-endopeptidase, neutral endopeptidase (NEP), Neprilysin, and common acute lymphoblastic leukemia antigen (CALLA), is a 90-110-kDa type II transmembrane glycoprotein normally expressed by a variety of tissues, including epithelial cells of the prostate, kidney, intestine, endometrium, adrenal glands, and lung. This zinc-dependent metalloprotease enzyme cleaves peptide bonds on the amino side of hydrophobic residues and inactivates a variety of physiologically active secreted peptides. CD20 is thought to be the rate-limiting degrading enzyme of amyloid β peptide (Aβ) whose abnormal misfolding and aggregation in neural tissue has been implicated in the development of Alzheimer's disease (AD). CD10 is also identified as the common acute lymphoblastic leukemia antigen (CALLA) present on leukemic cells of pre-B phenotype, and thus serves as the most important biomarker in the diagnosis of human acute lymphocytic leukemia (ALL).

Neprilysin Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
DexecadotrilPhase 3 ClinicalBioprojet Pharma
Gastrointestinal Diseases
Details
Sacubitril/Valsartan (Chong Kun Dang Pharmaceutical)CKD-202APhase 3 ClinicalChong Kun Dang Pharmaceutical Corp
Essential Hypertension
Details
QR-12000QR-12000Phase 3 ClinicalWuhan Createrna Science and Technology Co Ltd
Essential Hypertension; Hypertension
Details
Debio-0827PL-37; Debio-0827Phase 2 ClinicalPharmaleads
Pain
Details
SacubitrilAHU-377Phase 2 ClinicalNovartis Pharma Ag
Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Diabetes Mellitus; Essential Hypertension; Heart Failure; Hypertension; Insulin Resistance; Metabolic Diseases
Details
Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital)Phase 1 ClinicalSouthern Medical University Zhujing Hospital
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Details
Sacubitril Valsartan Sodium Extended-Relesae Tablets(Taizhou Overseas Pharma)Phase 1 ClinicalTaizhou Overseas Pharmaceuticals Co Ltd
Heart Failure
Details
Sacubitril/Allisartan Isoproxil/Amlodipine BesylatePhase 1 ClinicalShenzhen Salubris Pharmaceuticals Co Ltd
Essential Hypertension
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Sacubitril/Allisartan IsoproxilAHU-377/EXP3174; S-086ApprovedShenzhen Salubris Pharmaceuticals Co Ltd信超妥Mainland ChinaEssential HypertensionShenzhen Salubris Pharmaceuticals Co Ltd2025-05-20
Essential Hypertension; Heart Failure; Hypertension
Details
Sacubitril/Valsartan Sodium HydrateLCZ-696; LCZ-696AApprovedNovartis Pharma AgENTRESTO SPRINKLE, Enresuto, Enrest, Entresto, Neparvis, 诺欣妥, 科畅欣United StatesHeart FailureNovartis Pharmaceuticals Corp2015-07-07
Breast Neoplasms; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Erectile Dysfunction; Essential Hypertension; Heart Defects, Congenital; Heart Diseases; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Hepatic Insufficiency; Hypertension; Lymphoma; Myocardial Infarction; Obesity; Peripheral Arterial Disease; Postmyocardial Infarction Syndrome; Renal Insufficiency; Renal Insufficiency, Chronic; Ventricular Dysfunction, Left
Details
RacecadotrilTiorfan; HidrasecApprovedBioprojet PharmaFranceDiarrheaBioprojet Pharma1993-03-23
Diarrhea; Diarrhea, Infantile; Sepsis
Details